Pharmaceutical gigs (NASDAQ: CNCE – Get a rating) was downgraded by stock analysts to StockNews.com from a “hold” rating to a “sell” rating in a research note released on Tuesday.
Other stock analysts have also recently released reports on the stock. Truist Financial raised its price target on Concert Pharmaceuticals shares from $22.00 to $25.00 and gave the stock a “buy” rating in a Tuesday, September 13 research report. Jonestrading assumed coverage for Concert Pharmaceuticals shares in a Wednesday, August 24 research note. They set a “buy” rating and a target price of $17.00 for the business.
Concert Pharmaceutical Price Performance
NASDAQ CNCE traded at $0.35 on Tuesday, reaching $5.14. 318,047 shares were traded, against an average volume of 461,194. Concert Pharmaceuticals has a 52-week low of $2.57 and a 52-week high of $7.37. The company has a market capitalization of $246.40 million, a price-earnings ratio of -1.60 and a beta of 0.50. The company’s 50-day moving average price is $5.78 and its two-hundred-day moving average price is $5.48.
Institutional investors weigh in on Concert Pharmaceuticals
Several institutional investors and hedge funds have recently changed their holdings in the CNCE. Nantahala Capital Management LLC acquired a new stake in shares of Concert Pharmaceuticals in Q2 worth $6,988,000. Tang Capital Management LLC bought a new position in Concert Pharmaceuticals in Q3 worth $6,720,000. Kynam Capital Management LP increased its stake in Concert Pharmaceuticals by 67.3% in Q3. Kynam Capital Management LP now owns 1,673,041 shares of the biotech company worth $11,209,000 after acquiring an additional 673,041 shares during the period. Assenagon Asset Management SA increased its stake in Concert Pharmaceuticals by 1,618.8% in the 2nd quarter. Assenagon Asset Management SA now owns 548,843 shares of the biotech company worth $2,311,000 after acquiring an additional 516,912 shares during the period. Finally, AWM Investment Company Inc. bought a new position in Concert Pharmaceuticals in Q2 worth $2,125,000. Institutional investors and hedge funds hold 82.77% of the company’s shares.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company developing novel small molecule drugs for the treatment of autoimmune diseases. The Company’s lead product candidate is CTP-543, which is in a Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune skin condition.
Further reading
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.
Before you consider Concert Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market spreads…and Concert Pharmaceuticals was not on the list.
Although Concert Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
